Lably
Skip to content

Defactinib

  • 1 min read
  • 1 chapters

Explore on Lably

ToursExplore Lably’s 3D tours

Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial. Subsequent research in patients with specific NF2 mutations also found limited activity.

As of 2022, it remains in trials in combination with other medications for other types of cancer.

More in Health

Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein